GHK-Cu research: studies, doses and safety

A copper-binding skin peptide with small topical studies and untested systemic injections.

Also called: Copper tripeptide-1, Glycyl-L-histidyl-L-lysine copper, Copper-GHK.

Healing and repair peptides · Copper-binding tripeptide complex.

A diabetic-foot-ulcer trial used GHK-Cu gel daily for up to eight weeks alongside wound care; this does not define an injection course.

17 human records include secondary reports, mixed products, historical phase 3 news and 1 recruiting trial. No verified systemic injection trial was found.

Key studies

  • Venous ulcers: no benefit: Copper-peptide cream did no better than vehicle. (source)
  • Diabetic ulcers: immediate and delayed gel: Immediate-start gel improved median plantar-ulcer area closure. (source)
  • Thigh skin: collagen biopsy pilot: Collagen-marker improvement was seen in 7/10 copper-peptide sites. (source)
  • Makeup formulations: conference report: The review reports improved skin ratings with both formulations. (source)
  • Facial cream: 71 women: Reviews report better skin appearance than control. (source)
  • Eye cream: 41 women: Reviews report improvement versus vehicle and vitamin K cream. (source)

Related to GHK-Cu

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.